SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
Top Cited Papers
Preprint
- 11 June 2020
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
SummaryA SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation.Keywords
This publication has 35 references indexed in Scilit:
- A SARS-like cluster of circulating bat coronaviruses shows potential for human emergenceNature Medicine, 2015
- Evaluation of candidate vaccine approaches for MERS-CoVNature Communications, 2015
- Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial VirusScience, 2013
- Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirusProceedings of the National Academy of Sciences of the United States of America, 2013
- Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing AntibodyScience, 2013
- A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon ChallengeJournal of Virology, 2011
- Proteolytic Activation of Influenza Viruses by Serine Proteases TMPRSS2 and HAT from Human Airway EpitheliumJournal of Virology, 2006
- Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape MutantsPLoS Medicine, 2006
- Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccinesJAMA, 1967
- Altered Reactivity to Measles VirusJAMA, 1967